ESMO Virtual Congress 2020: TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan in Metastatic Urothelial Cancer that Has Progressed After Platinum and Checkpoint Inhibitors

(UroToday.com) Dr. Yohann Loriot presented the final results of the TROPHY-U-01 study, which was a phase 2 study of Sacituzumab Govitecan (anti-Trop-2) in metastatic urothelial carcinoma (mUC) patients who have progressed after platinum and checkpoint inhibitor therapy.¹